Nature Communications (Jan 2017)
CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma
- Jin Zhou,
- Zhong Wu,
- Gabrielle Wong,
- Eirini Pectasides,
- Ankur Nagaraja,
- Matthew Stachler,
- Haikuo Zhang,
- Ting Chen,
- Haisheng Zhang,
- Jie Bin Liu,
- Xinsen Xu,
- Ewa Sicinska,
- Francisco Sanchez-Vega,
- Anil K. Rustgi,
- J. Alan Diehl,
- Kwok-Kin Wong,
- Adam J. Bass
Affiliations
- Jin Zhou
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Zhong Wu
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Gabrielle Wong
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Eirini Pectasides
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Ankur Nagaraja
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Matthew Stachler
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Haikuo Zhang
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Ting Chen
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Haisheng Zhang
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Jie Bin Liu
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Xinsen Xu
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Ewa Sicinska
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Francisco Sanchez-Vega
- Division of Computational Biology, Memorial Sloan-Kettering Cancer Center
- Anil K. Rustgi
- Department of Medicine, University of Pennsylvania School of Medicine
- J. Alan Diehl
- Department of Biochemistry and Molecular Biology, Hollings Cancer Center, The Medical University of South Carolina
- Kwok-Kin Wong
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Adam J. Bass
- Department of Medical Oncology, Dana-Farber Cancer Institute
- DOI
- https://doi.org/10.1038/ncomms13897
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 12
Abstract
Oesophageal squamous cell carcinoma often develop resistance to EGFR tyrosine kinase inhibitors. Here, the authors demonstrate that inhibition of cell cycle regulators CDK4/6 or MAPK blockade enhances the efficacy of EGFR inhibitors for these tumours in mice.
